Hidden fields
Books Books
" ... cetera. We have developed certain inhouse biological availability requirements for abbreviated new drug applications but information and techniques thus far in this whole area have been slow in coming and must be considered preliminary. On the basis... "
Competitive problems in the drug industry: hearings before Subcommittee on ... - Page 7988
by United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly and Anticompetitive Activities, United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly - 1967
Full view - About this book

Competitive Problems in the Drug Industry, Volume 3, Part 20; Volume 20

United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly - Drugs - 1971 - 290 pages
...of what are the various factors that go into developing uniformity for these drugs. Senator NELSON. Well, then, will these become additional factors in...new drug approval and surveillance, and all of the NAS-NEC evaluations, are in fact to no avail unless the results are communicated to the prescribing...
Full view - About this book

Competitive Problems in the Drug Industry, Volume 21

United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly - Pharmaceutical industry - 1971 - 304 pages
...as well as brand name. Even though there have been definite indications that different brands of the few drugs in chemically equivalent formulations have...reason to believe this is not a frequent phenomenon. COMMUNICATIONS WITH THE PROFESSION AND WITH FEDERAL DRUG PURCHASERS All of the FDA's scientific work...
Full view - About this book

Competitive Problems in the Drug Industry: Hearings, Ninetieth Congress ...

United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly - Pharmaceutical industry - 1973 - 834 pages
...by FDA they would be equally effective at the same dose. Recently, however, there have been definite indications that different brands of a few drugs in...given significantly different biological responses. The recent example of chloramphenicol has been widely publicized. Were this a frequent phenomenon,...
Full view - About this book

Hearings, Reports and Prints of the Senate Select Committee on ..., Parts 20-22

United States. Congress. Senate. Select Committee on Small Business - Legislative hearings - 1971 - 1192 pages
...as well as brand name. Even though there have been definite indications that different brands of the few drugs in chemically equivalent formulations have...reason to believe this is not a frequent phenomenon. COMMUNICATIONS WITH THE PROFESSION AND WITH FEDERAL DRUG PURCHASERS All of the FDA's scientific work...
Full view - About this book

Health Maintenance Organizations: Hearings . . . Ninety-second Congress ...

United States. Congress. House. Committee on Interstate and Foreign Commerce. Subcommittee on Public Health and Environment - Group medical practice - 1972 - 456 pages
...essentially the same availability as measured by blood levels, excretion, and absorption profiles, ct cetera. We have developed certain in-house biological...reason to believe this is not a frequent phenomenon. Duplicative Drug8 Sen. Nelson. Is there any sound reason for permitting the introduction into the marketplace...
Full view - About this book

National Health Insurance Proposals: Hearings, Ninety-second Congress, First ...

United States. Congress. House. Committee on Ways and Means - Health insurance - 1972 - 1344 pages
...essentially the same availability as measured by blood levels, excretion, and absorption profiles, ct cetera. We have developed certain in-house biological...reason to believe this is not a frequent phenomenon. Duplit* ulive Drugs Sen. Nelson. Is there any sound reason for permitting the introduction into the...
Full view - About this book

Competitive Problems in the Drug Industry: Hearings, Ninetieth Congress ...

United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly - Pharmaceutical industry - 1973 - 836 pages
...by FDA they would be equally effective at the same dose. Recently, however, there have been definite indications that different brands of a few drugs in...given significantly different biological responses. The recent example of chloramphenlcol has been widely publicized. Were this a frequent phenomenon,...
Full view - About this book




  1. My library
  2. Help
  3. Advanced Book Search
  4. Download EPUB
  5. Download PDF